Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Benefits of lixilan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial
Mahmoud Nassar, MD, PhD, from the Department of Medicine, Division of Endocrinology, Diabetes and Metabolism at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, who was not involved in this research, noted the following about the study to Medical News Today : Using national Medicare data, the study employs a robust target trial emulation design and leverages rigorous propensity score matching to balance demographic and clinical factors
Breastfed infants whose mothers are thiamin deficient are vulnerable to developing infantile beriberi
This IV packs a powerful punch to guard your immune system
US$ 22.02
US$ 26.82
US$ 20.63
US$ 27.72
US$ 24.79
US$ 28.72
US$ 25.36
US$ 24.28
US$ 21.50
US$ 20.46
